Ursodeoxycholic acid treatment in patients with cystic fibrosis at risk for liver disease

BackgroundMeconium ileus has been detected as a risk factor for development of liver disease in cystic fibrosis, with influence on morbidity and mortality.AimsTo evaluate the effect of early treatment with ursodeoxycholic acid in patients with cystic fibrosis and meconium ileus to prevent chronic hepatic involvement and to explore the potential role of therapy on clinical outcomes.Methods26 cystic fibrosis patients with meconium ileus (16 M, mean age 8,4 years, range 3,5–9) were assigned to two groups: group 1 (14 patients) treated early with ursodeoxycholic acid (UDCAe); group 2 (12 patients) treated with ursodeoxycholic acid at the onset of cystic fibrosis liver disease (UDCAd). Anthropometric data, pulmonary function tests, pancreatic status, complications such as diabetes, hepatic involvement and Pseudomonas aeruginosa colonisation were compared among groups.ResultsA higher prevalence of cystic fibrosis chronic liver disease was observed in the UDCAd group with a statistically significant difference at 9 years of age (p < 0.05). Chronic infection by P. aeruginosa was found in 7% of UDCAe and 33% of UDCAd (p < 0.05). No differences were observed in nutritional status and other complications.ConclusionsEarly treatment with ursodeoxycholic acid may be beneficial in patients at risk of developing cystic fibrosis chronic liver disease such as those with meconium ileus. Multicentre studies should be encouraged to confirm these data.